Safety of menstrual blood-derived stromal cell transplantation in treatment of intrauterine adhesion

Figure 1 Histopathological analysis of intrauterine adhesion rats after menstrual-derived stromal stem cell treatment. Representative H&E staining of various organs (brain, heart, liver, spleen, lungs, kidneys, thymus, adrenal glands, uterus, and ovaries). No structural changes or injuries were detected in theses organs. Scale bar = 100 μm.

Figure 2 Tumorigenicity analysis of menstrual-derived stromal stem cells on nude mice 4 wk after subcutaneous injection. Representative photographs show the cell proliferation of menstrual-derived stromal stem cells (MenSCs) on nude mice 4 wk after subcutaneous injection. Fluorescent expression, which represented the MenSCs, gradually decreased over time. No metastatic or proliferative fluorescent signals were detected in other parts of the body.

Figure 3 Tumorigenicity analyses of menstrual-derived stromal stem cells and Hela cells in soft-agar colony formation assay. A: Representative photomicrographs show the cell malignant proliferation of 2500 and 5000 menstrual-derived stromal stem cells (MenSCs) after 1 and 2 wk of culturing. No cell colony was formed in the MenSCs group. B: Representative photomicrographs show the cell malignant proliferation of 2500 and 5000 HELA cells after 1 and 2 wk of culturing. Scale bar = 100 μm. MenSCs: Menstrual-derived stromal stem cells.